Cereno Scientific releases Insights video season 2 episode 5 with Phil B. Adamson, Abbott
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that episode 5 of season 2 in the Insights Video Series has been released. The video highlights the cutting-edge technology CardioMEMS HR System, used in the Phase II study of CS1 through a collaboration agreement with Abbott, and its future potential in personalized medicine for the rare disease pulmonary arterial hypertension (PAH). Participating in the video is Phil B. Adamson, MD, MSc Divisional Vice President and Chief Medical Officer of the Heart Failure Division, Abbott, and collaborative partner in the Phase II study of CS1.
Watch here: Insights Series S2E5: Phil Adamson, Abbott, about personalized medicine in PAH with CardioMEMS™ >
Drug candidate CS1 is currently being evaluated in a Phase II study as a treatment for the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. An investigator-initiated patient case study on the first patient having completed the study at the clinic the investigator was performed earlier this summer with remarkable data. Recently, positive findings from a data quality control review initiative of the ongoing study were also released. The study is designed to randomize 30 PAH patients and the top-line result of the Phase II study is estimated to be reported in Q1 2024.
The Insights Series is conducted as a series of interviews and conversations with internationally renowned scientific experts, who share their knowledge and insights to provide a greater understanding of the company's intensified focus on further developing the product portfolio. Season 2 of the video series was recorded at the ESC Congress in August 2023.
The video series is available on Cereno’s website, LinkedIn and YouTube.
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.